Canagliflozin and Cardiovascular disease- results of the CANVAS trial
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Community Hospital Internal Medicine Perspectives"
DOI: 10.1080/20009666.2018.1521245
Abstract: ABSTRACT Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium–glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to… read more here.
Keywords: trial; canagliflozin cardiovascular; results canvas; canvas trial ... See more keywords